USP39 Deubiquitinase Is Essential forKRASOncogene-driven Cancer

Spliceosomal DEAH-Box ATPases Remodel Pre-mRNA to Activate Alternative Splice Sites

(2016) Daniel R. Semlow et al.   CELL

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

(2016) Chiara Ambrogio et al.   NATURE MEDICINE

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

(2016) P. Lito et al.   SCIENCE

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

(2016) M. P. Patricelli et al.   Cancer Discovery

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

(2016) Sara Costa-Cabral et al.   PLoS One

KRAS as a Therapeutic Target

(2015) F. McCormick   CLINICAL CANCER RESEARCH

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

(2015) J. Downward   CLINICAL CANCER RESEARCH

Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure

(2015) R. Pagliarini et al.   EMBO REPORTS

The spliceosome is a therapeutic vulnerability in MYC-driven cancer

(2015) Tiffany Y.-T. Hsu et al.   NATURE

Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas

(2015) Julia M. Fraile et al.   Oncotarget

Dragging Ras Back in the Ring

(2014) Andrew G. Stephen et al.   CANCER CELL

Emerging Potential of Therapeutic Targeting of Ubiquitin-Specific Proteases in the Treatment of Cancer

(2014) A. Pal et al.   CANCER RESEARCH

A selective USP1–UAF1 inhibitor links deubiquitination to DNA damage responses

(2014) Qin Liang et al.   Nature Chemical Biology

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Applying Synthetic Lethality for the Selective Targeting of Cancer

(2014) Donal P. McLornan et al.   NEW ENGLAND JOURNAL OF MEDICINE

USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer

(2014) J Pan et al.   ONCOGENE

The crystal structure of S. cerevisiae Sad1, a catalytically inactive deubiquitinase that is broadly required for pre-mRNA splicing

(2014) H. Hadjivassiliou et al.   RNA

RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells

(2014) Simona Lamba et al.   Cell Reports

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies

(2014) Glenn S Cowley et al.   Scientific Data

Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer

(2013) Balázs Győrffy et al.   PLoS One

Ectopic Activation of Germline and Placental Genes Identifies Aggressive Metastasis-Prone Lung Cancers

(2013) S. Rousseaux et al.   Science Translational Medicine

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions

(2013) Daehwan Kim et al.   GENOME BIOLOGY

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

(2012) Ryan B. Corcoran et al.   CANCER CELL

TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers

(2012) Anurag Singh et al.   CELL

The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer

(2012) Madhu S. Kumar et al.   CELL

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies

(2012) Michael Steckel et al.   CELL RESEARCH

The development and application of small molecule modulators of SF3b as therapeutic agents for cancer

(2012) Thomas R. Webb et al.   DRUG DISCOVERY TODAY

Dynamic Protein-Protein Interaction Wiring of the Human Spliceosome

(2012) Anna Hegele et al.   MOLECULAR CELL

USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor

(2012) Long Zhang et al.   NATURE CELL BIOLOGY

USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma

(2012) Pieter J A Eichhorn et al.   NATURE MEDICINE

The spliceosome as a target of novel antitumour drugs

(2012) Sophie Bonnal et al.   NATURE REVIEWS DRUG DISCOVERY

Selective requirement for Mediator MED23 in Ras-active lung cancer

(2012) X. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Usp39 is essential for mitotic spindle checkpoint integrity and controls mRNA-levels of Aurora B

(2011) Renske J. van Leuken et al.   CELL CYCLE

Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A

(2011) A. Corrionero et al.   GENES & DEVELOPMENT

Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP9X and Mcl-1

(2011) C. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Atypical mechanism of NF-κB activation by TRE17/ubiquitin-specific protease 6 (USP6) oncogene and its requirement in tumorigenesis

(2011) L M Pringle et al.   ONCOGENE

Deubiquitinases in cancer: new functions and therapeutic options

(2011) J M Fraile et al.   ONCOGENE

Protease addiction and synthetic lethality in cancer

(2011) José Freije   Frontiers in Oncology

Sensitivity to Poly(ADP-ribose) Polymerase (PARP) Inhibition Identifies Ubiquitin-specific Peptidase 11 (USP11) as a Regulator of DNA Double-strand Break Repair

(2010) Timothy D. Wiltshire et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models

(2010) Silvestre Vicent et al.   JOURNAL OF CLINICAL INVESTIGATION

Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi

(2010) Johannes Zuber et al.   NATURE BIOTECHNOLOGY

Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells

(2010) Y Wang et al.   ONCOGENE

Regulation and Cellular Roles of Ubiquitin-Specific Deubiquitinating Enzymes

(2009) Francisca E. Reyes-Turcu et al.   Annual Review of Biochemistry

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

(2009) Anurag Singh et al.   CANCER CELL

Defining the Human Deubiquitinating Enzyme Interaction Landscape

(2009) Mathew E. Sowa et al.   CELL

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL

Suppression of Cancer Cell Growth by Promoting Cyclin D1 Degradation

(2009) Jing Shan et al.   MOLECULAR CELL

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

Breaking the chains: structure and function of the deubiquitinases

(2009) David Komander et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The emerging role of splicing factors in cancer

(2008) Ana Rita Grosso et al.   EMBO REPORTS

Ras oncogenes: split personalities

(2008) Antoine E. Karnoub et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY